MRNA Stock Rockets As FDA Clears New Flu Vaccine

Moderna Inc. stocks have been trading up by 191.45 percent on optimism over breakthrough mRNA pipeline advancements

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For MRNA Traders

FDA approval of the mFLUSIVA flu shot gives Moderna a fourth U.S. product, with a 2026–27 launch window and global reviews in Australia, Canada, and Europe already underway.
Q2 2026 from Moderna showed a narrower loss, slight revenue growth, and beats on both EPS and revenue, while management reaffirmed a 10% 2026 growth target and boosted its cash outlook.
The company cut its 2026 cost‑of‑sales outlook to $1.7B, flagged heavy Q3 revenue weighting, and still plans a roughly 50/50 U.S.–international revenue split.
Major banks, including Citi and Goldman Sachs, raised their MRNA price targets while sticking with Neutral ratings, signaling improving but cautious Wall Street confidence.
A new CEPI‑backed Phase 1 trial of the Bundibugyo ebolavirus vaccine broadens Moderna’s mRNA pipeline, even as a key norovirus Phase 3 study failed early criteria.

Quick Financial Overview

MRNA just reminded the market how violent biotech moves can be. After grinding between roughly $55 and $65 for weeks, the stock exploded from a $116.02 open to a $174.38 close on 2026/08/19. Intraday, MRNA printed a wild $114.46 low and $176.66 high. That is a huge range for a large‑cap name and screams “news catalyst plus crowded positioning.”

Under the hood, Moderna is still a cash‑burn story. Q2 2026 revenue was about $1.94B, but the company booked a net loss of $782M, or -$1.97 per share. EBITDA came in at roughly -$734M, with an EBIT margin around -139%. Profitability metrics are ugly across the board.

But MRNA holds about $5.14B in cash and short‑term investments and a current ratio near 2.3, so liquidity is not the near‑term issue. With enterprise value near $21.2B and a price‑to‑sales ratio around 11.45, traders are clearly paying up for platform optionality and not current earnings. The asset‑turnover ratio of 0.2 and heavy R&D run‑rate show a company still firmly in build‑out mode.

More Breaking News

For short‑term trading, this mix – big losses, strong balance sheet, and a headline‑driven spike – typically means elevated volatility, sharp squeezes, and fast reversals around every new data point.

Why Traders Are Watching MRNA After mFLUSIVA Approval

The core story driving MRNA’s latest surge is simple: Moderna is no longer a one‑trick COVID pony. The FDA just approved mFLUSIVA, its mRNA‑1010 seasonal flu vaccine for adults 50+. This is Moderna’s fifth global product and fourth FDA‑approved product, with a U.S. launch targeted for the 2026–27 respiratory virus season. For traders, that de‑risks a major part of the medium‑term revenue story.

MRNA’s flu win also plugs neatly into management’s guidance. The company is targeting up to 10% revenue growth off 2025 levels, and it expects 2026 revenue to be evenly split between U.S. and international markets. With additional mFLUSIVA reviews running in Australia, Canada, and Europe, Moderna now has a shot at a diversified respiratory franchise instead of a single‑country COVID stream.

Earnings are still red, but execution is tightening. In Q2 2026, Moderna reported a narrower loss, slight year‑over‑year revenue growth, and beats on both revenue and EPS. It trimmed its 2026 cost‑of‑sales outlook to $1.7B from $1.8B and guided that 55% of second‑half 2026 revenue will land in Q3. That front‑loads expectations into one quarter – and sets up a clear volatility event every time Q3 draws near.

The pipeline remains a double‑edged sword for MRNA. A key norovirus Phase 3 trial failed early success criteria, reminding traders that not every program will pay off. At the same time, the oncology and rare disease franchise – including intismeran and mRNA‑4157 with Merck in melanoma and a pivotal program in propionic acidemia – stays on track for pivotal data in 2026. Add in the new CEPI‑funded Phase 1 trial of mRNA‑1469 for Bundibugyo ebolavirus, and Moderna is clearly doubling down on breadth.

Wall Street is responding, but not with full‑throttle enthusiasm. Citi lifted its MRNA price target to $60 from $41. Goldman Sachs raised its target to $67 from $49. Yet both kept Neutral ratings, and the broader consensus still sits around a Hold with average targets in the low‑to‑mid $50s. Translation for traders: sentiment is thawing, but the street wants proof that flu launches and 2026 data will justify the premium.

Conclusion

For active traders, MRNA is shifting from a fading COVID story to a multi‑catalyst mRNA platform. The mFLUSIVA approval locks in a new commercial growth leg starting in the 2026–27 season, and parallel regulatory work outside the U.S. supports management’s push toward a balanced global revenue mix. Meanwhile, Q2 2026 numbers, while deeply loss‑making, showed narrower losses, a revenue beat, and tighter cost guidance – enough to trigger fresh price‑target hikes from big‑name banks.

At the same time, Moderna’s financials make it clear why many longer‑term players remain cautious. R&D is still running near $2.9B a year, free cash flow was about -$563M in the quarter, and margins are sharply negative. The failed norovirus Phase 3 readout is a reminder that a high‑beta pipeline cuts both ways. For MRNA, execution on mFLUSIVA launch, upcoming respiratory products, and 2026 oncology and rare disease readouts will decide whether this is the start of a durable re‑rating or just another biotech spike that fades.

This is exactly the kind of name Tim Sykes’ community watches closely: big range, strong news, and clear event dates where sentiment can flip fast. As Tim likes to say, “Patterns repeat, but traders don’t always pay attention.” That’s where a rules‑based trading mindset matters. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. For MRNA, the pattern right now is textbook momentum off a major catalyst – and disciplined traders will be watching the chart, the volume, and every new headline, ready to cut losses quickly and not overstay any move.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!